 | • レポートコード：MRC308GR09515 • 出版社/出版日：GlobalInfoResearch / 2023年8月 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医療 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
GlobalInfoResearchの最新の調査によると、世界の非定型奇形性ラブドイド腫瘍（ATRT）治療の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界の非定型奇形性ラブドイド腫瘍（ATRT）治療市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。
市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。
本レポートの主な目的は次のとおりです。
– 世界および主要国の市場機会の規模を決定するため
– 非定型奇形性ラブドイド腫瘍（ATRT）治療の成長可能性を評価するため
– 各製品および最終用途市場の将来の成長を予測するため
– 市場に影響を与える競争要因を評価するため
非定型奇形性ラブドイド腫瘍（ATRT）治療市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。
種類別セグメント
・手術、化学療法、放射線療法、標的免疫療法
用途別セグメント
・診療所、病院、その他
主要な市場プレーヤー
・Takeda Pharmaceutical Company、Vyriad Inc、Novartis Oncology、Istari Oncology Inc.、Secura Bio, Inc.、Pfizer, Inc.、Ipsen Pharma、Exelixis, Inc.
地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）
本調査レポートの内容は計15章あります。
・第1章では、非定型奇形性ラブドイド腫瘍（ATRT）治療製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な非定型奇形性ラブドイド腫瘍（ATRT）治療メーカーの企業概要、2019年～2022年までの非定型奇形性ラブドイド腫瘍（ATRT）治療の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な非定型奇形性ラブドイド腫瘍（ATRT）治療メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別非定型奇形性ラブドイド腫瘍（ATRT）治療の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの非定型奇形性ラブドイド腫瘍（ATRT）治療の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での非定型奇形性ラブドイド腫瘍（ATRT）治療市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および非定型奇形性ラブドイド腫瘍（ATRT）治療の産業チェーンを掲載しています。
・第14、15章では、非定型奇形性ラブドイド腫瘍（ATRT）治療の販売チャネル、販売業者、顧客、調査結果について説明します。
***** 目次(一部) *****
・市場概要
– 非定型奇形性ラブドイド腫瘍（ATRT）治療の概要
– 種類別分析（2018年vs2022年vs2029年）：手術、化学療法、放射線療法、標的免疫療法
– 用途別分析（2018年vs2022年vs2029年）：診療所、病院、その他
– 世界の非定型奇形性ラブドイド腫瘍（ATRT）治療市場規模・予測
– 世界の非定型奇形性ラブドイド腫瘍（ATRT）治療生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Takeda Pharmaceutical Company、Vyriad Inc、Novartis Oncology、Istari Oncology Inc.、Secura Bio, Inc.、Pfizer, Inc.、Ipsen Pharma、Exelixis, Inc.
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・種類別分析2018年-2029年：手術、化学療法、放射線療法、標的免疫療法
・用途別分析2018年-2029年：診療所、病院、その他
・非定型奇形性ラブドイド腫瘍（ATRT）治療の北米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・非定型奇形性ラブドイド腫瘍（ATRT）治療のヨーロッパ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・非定型奇形性ラブドイド腫瘍（ATRT）治療のアジア市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・非定型奇形性ラブドイド腫瘍（ATRT）治療の南米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・非定型奇形性ラブドイド腫瘍（ATRT）治療の中東・アフリカ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論
1 Market Overview
1.1 Product Overview and Scope of Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Surgery
1.3.3 Chemotherapy
1.3.4 Radiation
1.3.5 Targeted Immunotherapy
1.4 Market Analysis by Application
1.4.1 Overview: Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Clinic
1.4.3 Hospital
1.4.4 Others
1.5 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Size & Forecast
1.5.1 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (2018-2029)
1.5.3 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Takeda Pharmaceutical Company
2.1.1 Takeda Pharmaceutical Company Details
2.1.2 Takeda Pharmaceutical Company Major Business
2.1.3 Takeda Pharmaceutical Company Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
2.1.4 Takeda Pharmaceutical Company Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Takeda Pharmaceutical Company Recent Developments/Updates
2.2 Vyriad Inc
2.2.1 Vyriad Inc Details
2.2.2 Vyriad Inc Major Business
2.2.3 Vyriad Inc Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
2.2.4 Vyriad Inc Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Vyriad Inc Recent Developments/Updates
2.3 Novartis Oncology
2.3.1 Novartis Oncology Details
2.3.2 Novartis Oncology Major Business
2.3.3 Novartis Oncology Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
2.3.4 Novartis Oncology Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Novartis Oncology Recent Developments/Updates
2.4 Istari Oncology Inc.
2.4.1 Istari Oncology Inc. Details
2.4.2 Istari Oncology Inc. Major Business
2.4.3 Istari Oncology Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
2.4.4 Istari Oncology Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Istari Oncology Inc. Recent Developments/Updates
2.5 Secura Bio, Inc.
2.5.1 Secura Bio, Inc. Details
2.5.2 Secura Bio, Inc. Major Business
2.5.3 Secura Bio, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
2.5.4 Secura Bio, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Secura Bio, Inc. Recent Developments/Updates
2.6 Pfizer, Inc.
2.6.1 Pfizer, Inc. Details
2.6.2 Pfizer, Inc. Major Business
2.6.3 Pfizer, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
2.6.4 Pfizer, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Pfizer, Inc. Recent Developments/Updates
2.7 Ipsen Pharma
2.7.1 Ipsen Pharma Details
2.7.2 Ipsen Pharma Major Business
2.7.3 Ipsen Pharma Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
2.7.4 Ipsen Pharma Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Ipsen Pharma Recent Developments/Updates
2.8 Exelixis, Inc.
2.8.1 Exelixis, Inc. Details
2.8.2 Exelixis, Inc. Major Business
2.8.3 Exelixis, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
2.8.4 Exelixis, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Exelixis, Inc. Recent Developments/Updates
3 Competitive Environment: Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment by Manufacturer
3.1 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Manufacturer (2018-2023)
3.2 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Revenue by Manufacturer (2018-2023)
3.3 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Manufacturer Market Share in 2022
3.4.2 Top 6 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Manufacturer Market Share in 2022
3.5 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market: Overall Company Footprint Analysis
3.5.1 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market: Region Footprint
3.5.2 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market: Company Product Type Footprint
3.5.3 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Size by Region
4.1.1 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Region (2018-2029)
4.1.2 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Region (2018-2029)
4.1.3 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Region (2018-2029)
4.2 North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029)
4.3 Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029)
4.4 Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029)
4.5 South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029)
4.6 Middle East and Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2029)
5.2 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Type (2018-2029)
5.3 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2029)
6.2 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Application (2018-2029)
6.3 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Application (2018-2029)
7 North America
7.1 North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2029)
7.2 North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2029)
7.3 North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Size by Country
7.3.1 North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2018-2029)
7.3.2 North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2029)
8.2 Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2029)
8.3 Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Size by Country
8.3.1 Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2018-2029)
8.3.2 Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Size by Region
9.3.1 Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2029)
10.2 South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2029)
10.3 South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Size by Country
10.3.1 South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2018-2029)
10.3.2 South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Size by Country
11.3.1 Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Drivers
12.2 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Restraints
12.3 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment and Key Manufacturers
13.2 Manufacturing Costs Percentage of Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment
13.3 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Production Process
13.4 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Typical Distributors
14.3 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table 1. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Takeda Pharmaceutical Company Basic Information, Manufacturing Base and Competitors
Table 4. Takeda Pharmaceutical Company Major Business
Table 5. Takeda Pharmaceutical Company Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
Table 6. Takeda Pharmaceutical Company Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Takeda Pharmaceutical Company Recent Developments/Updates
Table 8. Vyriad Inc Basic Information, Manufacturing Base and Competitors
Table 9. Vyriad Inc Major Business
Table 10. Vyriad Inc Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
Table 11. Vyriad Inc Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Vyriad Inc Recent Developments/Updates
Table 13. Novartis Oncology Basic Information, Manufacturing Base and Competitors
Table 14. Novartis Oncology Major Business
Table 15. Novartis Oncology Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
Table 16. Novartis Oncology Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Novartis Oncology Recent Developments/Updates
Table 18. Istari Oncology Inc. Basic Information, Manufacturing Base and Competitors
Table 19. Istari Oncology Inc. Major Business
Table 20. Istari Oncology Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
Table 21. Istari Oncology Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Istari Oncology Inc. Recent Developments/Updates
Table 23. Secura Bio, Inc. Basic Information, Manufacturing Base and Competitors
Table 24. Secura Bio, Inc. Major Business
Table 25. Secura Bio, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
Table 26. Secura Bio, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Secura Bio, Inc. Recent Developments/Updates
Table 28. Pfizer, Inc. Basic Information, Manufacturing Base and Competitors
Table 29. Pfizer, Inc. Major Business
Table 30. Pfizer, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
Table 31. Pfizer, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Pfizer, Inc. Recent Developments/Updates
Table 33. Ipsen Pharma Basic Information, Manufacturing Base and Competitors
Table 34. Ipsen Pharma Major Business
Table 35. Ipsen Pharma Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
Table 36. Ipsen Pharma Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Ipsen Pharma Recent Developments/Updates
Table 38. Exelixis, Inc. Basic Information, Manufacturing Base and Competitors
Table 39. Exelixis, Inc. Major Business
Table 40. Exelixis, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
Table 41. Exelixis, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Exelixis, Inc. Recent Developments/Updates
Table 43. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 44. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Revenue by Manufacturer (2018-2023) & (USD Million)
Table 45. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 46. Market Position of Manufacturers in Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 47. Head Office and Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Production Site of Key Manufacturer
Table 48. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market: Company Product Type Footprint
Table 49. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market: Company Product Application Footprint
Table 50. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment New Market Entrants and Barriers to Market Entry
Table 51. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 52. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 53. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 54. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 55. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 56. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Region (2018-2023) & (US$/Unit)
Table 57. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Region (2024-2029) & (US$/Unit)
Table 58. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 59. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 60. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 61. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 62. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Type (2018-2023) & (US$/Unit)
Table 63. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Type (2024-2029) & (US$/Unit)
Table 64. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 65. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 66. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 67. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 68. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Application (2018-2023) & (US$/Unit)
Table 69. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Application (2024-2029) & (US$/Unit)
Table 70. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 71. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 72. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 73. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 74. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 75. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 76. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 77. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 78. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 79. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 80. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 81. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 82. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 83. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 84. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 85. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 86. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 87. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 88. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 89. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 90. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 91. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 92. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 93. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 94. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 95. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 96. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 97. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 98. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 99. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 100. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 101. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 102. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 103. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 104. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 105. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 106. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 107. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 108. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 109. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 110. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Raw Material
Table 111. Key Manufacturers of Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Raw Materials
Table 112. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Typical Distributors
Table 113. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Typical Customers
List of Figures
Figure 1. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Picture
Figure 2. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Type in 2022
Figure 4. Surgery Examples
Figure 5. Chemotherapy Examples
Figure 6. Radiation Examples
Figure 7. Targeted Immunotherapy Examples
Figure 8. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 9. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Application in 2022
Figure 10. Clinic Examples
Figure 11. Hospital Examples
Figure 12. Others Examples
Figure 13. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price (2018-2029) & (US$/Unit)
Figure 17. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Type (2018-2029) & (US$/Unit)
Figure 32. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Application (2018-2029) & (US$/Unit)
Figure 35. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Region (2018-2029)
Figure 55. China Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Drivers
Figure 76. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Restraints
Figure 77. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment in 2022
Figure 80. Manufacturing Process Analysis of Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment
Figure 81. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source